INS and metabolic syndrome: Based on the data analysis presented in Table 3, there are two compounds and eight peptides that have the potential to become drug candidates targeting metabolic syndrome, including compounds C3 and C6 as well as peptides P1, P2, P3, P4, P5, P6, P8, and P9, which have potential value demonstrated by the Pa value of insulin promoter excretion in relation to metabolic syndrome.